Revolution Medicines: Mancini sells 811 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Revolution Medicines, Inc. Chief Global Commercialization Officer Anthony Mancini exercised options to acquire 810 common shares at a $33.62 exercise price and one share at $102.02 on November 9, 2026, and sold 811 common shares at $200 per share.
The transactions were made pursuant to a Rule 10b5-1 trading plan Anthony Mancini adopted on June 11, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 811 shares ($135K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Mancini Anthony
Role
See Remarks
Sold
811 shs ($162K)
Approx. gross sale proceeds
$162K
Approx. exercise cost
$27K
Approx. pre-tax spread
$135K
Share of Position Sold
2.0%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 810 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F4 | 1 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 810 | $33.62 | $27K |
| Exercise | Common Stock F1 | 1 | $102.02 | $102.02 |
| Sale | Common Stock F1, F2 | 811 | $200.00 | $162K |
Holdings After Transaction:
Stock Option (Right to Buy) — 116,704 options (Direct);
Common Stock — 39,765 shares (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 117,515 to 116,704 options (Direct);
Common Stock, 39,765 to 39,765 shares (Direct)
Footnotes (4)
- F1. Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.
- F2. Includes 39,575 restricted stock units.
- F3. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
- F4. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Key Figures
Shares sold and sale price: 811 shares at $200 per share
Option exercise price: $33.62 per share
Option exercise price: $102.02 per share
+1 more
4 metrics
Shares sold and sale price
811 shares at $200 per share
Common stock sold November 9, 2026
Option exercise price
$33.62 per share
Option exercise covering 810 common shares on November 9, 2026
Option exercise price
$102.02 per share
Option exercise covering 1 common share on November 9, 2026
Restricted stock units
39,575 units
Included in the post-transaction amount associated with the sale
Key Terms
10b5-1 trading plan, restricted stock units, Vesting Commencement Date
3 terms
10b5-1 trading plan regulatory
"the transactions made pursuant to a 10b5-1 trading plan"
A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.
restricted stock units financial
"Includes 39,575 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Vesting Commencement Date financial
"the option's Vesting Commencement Date measured from April 1, 2025"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did RVMD Chief Global Commercialization Officer Anthony Mancini sell?
Anthony Mancini sold 811 Revolution Medicines common shares at $200 per share on November 9, 2026. The report also records same-day option exercises covering 811 common shares. The transactions were made under a Rule 10b5-1 trading plan adopted by Mancini on June 11, 2026.
What were the vesting terms for Anthony Mancini's RVMD options?
The 810-share option's terms set 25% to vest on the first anniversary measured from April 1, 2025, then 1/48 monthly, with full vesting and exercisability as of the fourth anniversary, subject to continued service through each vesting date. The 1-share option was scheduled to vest 1/48 monthly from March 1, 2026, under the same four-year and continued-service condition.
AI-generated analysis. How Rhea-AI works. Not financial advice.
